What is it about?
As nucleotide analogues, thiopurines efficiently maintain control of immune mediated disease. The indication for a large use of thiopurines in the maintenance of inflammatory bowel disease (IBD) has come of age based on economic and medical issues: (1) IBD management costs fall to nadir during remission periods; (2) Patients’ quality of life is best when the IBD is in control. Shown to achieve mucosal healing, , thiopurines have now entered modern treat-to-target IBD algorithms.
Featured Image
Photo by Thought Catalog on Unsplash
Why is it important?
This paper provides definitive summary that thiopurines are still the drugs to beat in IBD in terms of: 1) Cost containment; 2) Mucosal Healing; 3) Reduction of colon neoplastic transformation.
Perspectives
I believe this paper might help those tending to believe that modern biological drugs can overshadow the indication for thiopurine in IBD: in fact, we hereby hold that as mucosal healing agents thiopurines carry more chances to behave as disease terminators that the biologics themselves, and in any case are crucial in co-administration regimes.
Giovanni Actis
Read the Original
This page is a summary of: A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms, Reviews on Recent Clinical Trials, January 2019, Bentham Science Publishers, DOI: 10.2174/1574887113666180910120959.
You can read the full text:
Resources
Contributors
The following have contributed to this page
